Edmonston-Zagreb measles vaccine

The Edmonston-Zagreb measles vaccine is a live attenuated viral vaccine developed to prevent measles infection. It contains the Edmonston-Zagreb strain of the measles virus, which is known for its immunogenicity even in the presence of maternal antibodies. The vaccine is primarily manufactured by the **Serum Institute of India**. In the context of the **Bandim Health Project**, this vaccine has been extensively studied in West Africa (Guinea-Bissau and Burkina Faso) to evaluate the efficacy and non-specific effects of an early two-dose schedule, where the first dose is administered at 4.5 months of age followed by a second dose at 9 months. These studies aim to reduce overall child mortality by providing earlier protection against measles and potentially leveraging beneficial non-specific immune stimulation.

Brand names

M-Vac

Other names

Edmonston-Zagreb strain measles vaccineEZ measles vaccineStandard-titre Edmonston-Zagreb measles vaccine